Citadel Advisors LLC increased its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 83.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 855,676 shares of the company's stock after buying an additional 389,247 shares during the quarter. Citadel Advisors LLC owned approximately 1.35% of ABIVAX Société Anonyme worth $6,264,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. R Squared Ltd acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $36,000. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock worth $3,105,000 after acquiring an additional 107,750 shares during the period. JPMorgan Chase & Co. bought a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $5,336,000. Franklin Resources Inc. increased its holdings in shares of ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock worth $10,732,000 after acquiring an additional 141,710 shares during the last quarter. Finally, Springhill Fund Asset Management HK Co Ltd bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $1,520,000. 47.91% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have commented on ABVX shares. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th.
Read Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
NASDAQ:ABVX traded up $0.25 during mid-day trading on Thursday, hitting $6.07. 23,707 shares of the stock were exchanged, compared to its average volume of 132,931. The firm's 50-day simple moving average is $6.39 and its 200 day simple moving average is $7.18. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $14.72.
ABIVAX Société Anonyme Profile
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
